%0 Journal Article
%T Ensayo cl赤nico fase I del anticuerpo monoclonal IOR-T1 en linfoma T: farmacocin谷tica y respuesta inmune
%A Mar赤a E. Faxas Garc赤a
%A Marta E. Guerra Yi
%A Alejandro 芍lvarez
%A Carlos Calder車n
%J Revista Cubana de Medicina
%D 2003
%I ECIMED
%X Como parte del ensayo cl赤nico fase I con el anticuerpo monoclonal murino IOR-T1 (AcM IOR-T1) con dosis repetidas (200-800 mg) en pacientes que padec赤an llinfoma T cut芍neo, se estudi車 la farmacocin谷tica y la respuesta contra la prote赤na del rat車n (HAMA) en los 10 pacientes tratados. Se observ車 una gran variaci車n individual en la concentraci車n m芍xima en suero estimada a las 2 h. El tiempo de vida media del AcM fue entre 13,93 y 19,6 h. La mayor赤a de los pacientes desarroll車 anticuerpos contra el AcM IOR-T1. La presencia de este segundo anticuerpo no alter車 significativamente la farmacocin谷tica del AcM administrado. As part of the stage I clinical trial with the murine monoclonal antibody IOR-T1 at repeated doses (200-800 mg) in patients carriers of cutaneous T-cell lymphoma, the pharmacokinetics and the response against the mouse protein (HAMA) were studied in the 10 patients under treatment. It was observed a great individual variation in the maximum concentration in serum, which was estimated at 2 hours. The mean life time of the monoclonal antibody was between 13.93 and 19.6 hours. Most of the patients developed antibodies against the monoclonal antibody IOR-T1. The presence of this second antibody did not alter signficantly the pharmacokinetics of the administered monoclonal antibody.
%K ENSAYOS CLINICOS FASE I
%K LINFOMA DE CELULA T CUTANEO
%K ANTICUERPOS MONOCLONALES
%K CLINICAL TRIALS
%K PHASE I
%K LYMPHOMA
%K T-CELL
%K CUTANEOUS
%K ANTIBODIES
%K MONOCLONAL
%U http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232003000200011